Palmitic acid dysregulates the Hippo–YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS–STING–IRF3 signaling mechanism

Impaired angiogenesis and wound healing carry significant morbidity and mortality in diabetic patients. Metabolic stress from hyperglycemia and elevated free fatty acids have been shown to inhibit endothelial angiogenesis. However, the underlying mechanisms remain poorly understood. In this study, we show that dysregulation of the Hippo–Yes-associated protein (YAP) pathway, an important signaling mechanism in regulating tissue repair and regeneration, underlies palmitic acid (PA)-induced inhibition of endothelial angiogenesis. PA inhibited endothelial cell proliferation, migration, and tube formation, which were associated with increased expression of mammalian Ste20-like kinases 1 (MST1), YAP phosphorylation/inactivation, and nuclear exclusion. Overexpression of YAP or knockdown of MST1 prevented PA-induced inhibition of angiogenesis. When searching upstream signaling mechanisms, we found that PA dysregulated the Hippo–YAP pathway by inducing mitochondrial damage. PA treatment induced mitochondrial DNA (mtDNA) release to cytosol, and activated cytosolic DNA sensor cGAS–STING–IRF3 signaling. Activated IRF3 bound to the MST1 gene promoter and induced MST1 expression, leading to MST1 up-regulation, YAP inactivation, and angiogenesis inhibition. Thus, mitochondrial damage and cytosolic DNA sensor cGAS–STING–IRF3 signaling are critically involved in PA-induced Hippo–YAP dysregulation and angiogenesis suppression. This mechanism may have implication in impairment of angiogenesis and wound healing in diabetes.

damage and mitochondrial DNA release, and activation of the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS)-interferon genes protein (STING)-interferon regulatory factor 3 (IRF3) pathway.

Palmitic acid inhibits endothelial proliferation, migration, and angiogenesis
To examine the effects of metabolic stress on endothelial angiogenesis, we treated human aortic endothelial cells (HAECs) with PA, the main type of free fatty acid in metabolic syndrome (24). We found that high concentrations of PA significantly reduced endothelial proliferation (Fig. 1, A and B) and impaired endothelial migration (Fig. 1C). HAECs were able to form tubules spontaneously. However, PA treatment severely destroyed tube formation, indicating angiogenesis deficiency (Fig. 1D). These findings suggest that PA inhibits endothelial proliferation, migration, and angiogenesis.

Palmitic acid activates MST1 and inhibits YAP
We next examined whether PA-induced inhibition of angiogenesis was associated with dysregulation of the Hippo-YAP pathway. As shown in Fig. 2A, PA induced MST1 expression and phosphorylation, indicative of MST1 activation. Consistently, PA induced YAP phosphorylation ( Fig. 2A) and nucleus exclusion (Fig. 2B), indicating its inactivation. Overexpression of wild type (WT) YAP not only promoted basal endothelial proliferation (Fig. 2C) and tube formation (Fig. 2D), but also prevented PA-induced reduction in endothelial proliferation (Fig. 2C) and tube formation (Fig. 2D). Overexpression of constitutively active YAP S127A mutant, in which mutation of the phosphorylation site in YAP results in its resistance to phosphorylation and inactivation (25), also exhibited protective effects (Fig.  2, C and D). In contrast, knocking down YAP with siRNA (supplemental Figs. S1A and S2A) not only reduced endothelial proliferation (supplemental Fig. S1, B and C) and tube formation (supplemental Fig. S1D) at basal conditions, but also amplified PA-induced inhibition of endothelial proliferation (supplemental Fig. S1, B and C) and tube formation (supplemental Fig. S1D). These results indicate that YAP inactivation underlies PA-induced inhibition of endothelial proliferation and angiogenesis.

MST1 is involved in palmitic acid-induced inhibition of endothelial angiogenesis
We then investigated the role of MST1 in the inhibition of YAP and endothelial angiogenesis. Knocking down MST1 (supplemental Fig. S2B) prevented PA-induced YAP phosphorylation (Fig. 3A) and cytoplasm retention (Fig. 3B). Additionally, silencing MST1 promoted endothelial proliferation at basal levels, and prevented PA-induced inhibition of endothelial proliferation (Fig. 3, C and D). Similarly, knocking down MST1 alle-viated PA-induced inhibition of tube formation (Fig. 3E). Together, these results suggest that MST1 is involved in PAinduced inactivation of YAP and impairment of endothelial angiogenesis.

PA induces mitochondrial DNA release to cytosol and activates the cytosolic DNA sensor cGAS-STING-IRF3 pathway
We further studied the mechanism by which PA activated MST1 and inhibited YAP and endothelial angiogenesis. One of the significant adverse effects of free fatty acid oversupply is mitochondrial damage that can trigger cell dysfunction and even cell death (26,27). Our recent study suggests that PA can cause mitochondrial damage and cytosolic release of mitochondria DNA (mtDNA) (28). Through cGAS (29 -31), cytosolic DNA including cytosolic mtDNA can be converted to second messenger cGAMP that activates DNA sensor STING-IRF3 signaling (32,33), leading to transcription of proinflammatory molecules and activation of inflammatory response. cGAS-STING-IRF3 signaling has been shown to mediate mitochondrial damage-induced inflammatory response (28) and cell dysfunction (34 -36). We asked whether this mechanism also mediated PA-induced angiogenesis suppression.
We first confirmed the effects of PA on mitochondrial function by measuring mitochondrial membrane potential (⌬ m ) using tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining. JC-1 is a cationic fluorescent dye that forms red aggregates in polarized functional mitochondria and stays as a green monomer outside depolarized mitochondria. We observed that PA treatment decreased red aggregates and increased green monomers with an increased green/red fluorescence ratio (Fig.  4A), indicating reduction in ⌬ m and mitochondrial dysfunction. Additionally, co-staining of double strand DNA (dsDNA) and mitochondria (MitoTracker) showed that PA treatment significantly increased cytosolic dsDNA (dsDNA that did not co-localize with either mitochondria or the nucleus) (28) (Fig.  4B). Further cytosolic mtDNA analysis (by PCR of cytosolic DNA with mtDNA sequences as primers) showed PA significantly increased cytosolic mtDNA (Fig. 4C). Furthermore, prolonged PA treatment increased the levels of cGAS, STING, phosphorylated IRF3 (Fig. 4D), suggesting activation of the cGAS-STING-IRF3 pathway. The up-regulation of cGAS-STING-IRF3 was associated with increased MST1 protein and YAP phosphorylation/inactivation (Fig. 4D).
Finally, inducing mitochondrial damage with carbonyl cyanide m-chlorophenyl hydrazone (CCCP), an agent that increases mitochondrial permeability and damage, increased levels of cGAS, STING, and phosphorylated IRF3 (Fig. 4E), and stimulated STING perinuclear translocation and IRF3 nuclear translocation (Fig. 4F), indicating a direct effect of mitochondrial damage in cGAS-STING-IRF3 activation. Together, these data suggest that PA treatment and mitochondrial  Western blot analysis showed that PA induced MST1 expression and phosphorylation, and YAP phosphorylation (n ϭ 6 biological repeats) (A). Representative images of immunostaining showed that PA prevented YAP nuclear translocation (n ϭ 6 biological repeats) (B). C and D, HAECs were transfected with the YAP mutation plasmid (YAP S127A) or wild type plasmid (WT), followed by PA treatment for 24 h. Representative images of BrdU analysis showed that overexpression of YAP WT or YAP S127A increased endothelial cell proliferation (n ϭ 4 biological repeats) (C). In vitro tube formation assay showed that overexpression of YAP WT or YAP S127A enhanced endothelial tube formation (n ϭ 4 biological repeats) (D).

Cross-talk between DNA sensor signaling and Hippo-Yap pathway
damage can result in cytosolic release of mtDNA and activation of cytosolic DNA sensor cGAS-STING-IRF3 signaling, which are associated with dysregulation of the Hippo-YAP pathway.

DNA sensor cGAS-STING-IRF3 signaling mediates PA-induced Hippo-YAP dysregulation
We further examined the involvement of the cGAS-STING-IRF3 pathway in the regulation of MST1 and YAP. Silencing cGAS (supplemental Fig. S2C) with siRNA inhibited PA-induced IRF3 phosphorylation, MST1 expression, and YAP phosphorylation (Fig. 5A), suggesting the involvement of cGAS in STING-IRF3 activation and Hippo-Yap dysregulation. Similarly, knocking down STING and IRF3 (supplemental Fig. S2, E and F) prevented PA-induced MST1 expression and YAP phosphorylation (Fig. 5B), and YAP cytosolic retention (Fig. 5C). These results indicate that the cGAS-STING-IRF3 pathway is critical to PA-induced MST1 up-regulation and YAP inhibition in endothelial cells.

IRF3 directly binds to MST1 promoter and mediates PA-induced induction of MST1 expression
We then asked how the cGAS-STING-IRF3 pathway regulates the Hippo-YAP pathway. It has been shown that activated MST1 promotes immune reaction and inflammatory response (38,39). Because IRF3 induces the transcription of proinflammatory factors (40), we asked whether IRF3 also promoted MST1 expression. Indeed, silencing STING and IRF3 with specific siRNA reduced PA-induced MST1 mRNA (Fig. 6A), suggesting that IRF3 regulates MST1 at the mRNA level. Sequencing analysis of the MST1 promoter revealed putative IRF3-binding sites in the 5Ј untranslated region (Fig. 6B) of the MST1 gene. Chromatin immunoprecipitation assay showed that IRF3 bound to the MST1 promoter (Fig. 6C), and this binding was enhanced by treating cells with PA or CCCP. Together, these findings suggest that IRF3 directly binds to the MST1 promoter and promotes MST1 expression in response to PA challenge and mitochondrial damage.

The cGAS-STING-IRF3 pathway is involved in PA-induced inhibition of endothelial angiogenesis
Finally, we show that silencing cGAS, STING, and IRF3 promoted endothelial proliferation at basal levels, and partially prevented PA-induced inhibition of endothelial proliferation (Fig. 7, A and B). Similarly, knocking down cGAS, STING, and IRF3 improved endothelial tube formation and reversed PAinduced impairment of endothelial angiogenesis (Fig. 7C). Together, these findings suggest a critical role of the cGAS-STING-IRF3 pathway in PA-induced inhibition of endothelial proliferation and angiogenesis.

Discussion
In this study, we show that PA dysregulates the Hippo-YAP pathway and inhibits angiogenesis. PA induces mitochondrial damage and cytosolic release of mtDNA, which activates the cytosolic DNA sensor cGAS-STING-IRF3 pathway. Activated IRF3 binds to the MST1 promoter and induces MST1 expression, leading to YAP phosphorylation/inactivation and angiogenesis suppression (Fig. 7D).
Although impaired angiogenesis and wound healing in diabetes is widely reported, the pathogenesis remains incomplete understood. Hippo-YAP (16,22) signaling is a key pathway in regulating tissue repair and angiogenesis. YAP, by inducing the expression of proangiogenic factors (22) and epithelial-to-mesenchymal transition (41) promotes angiogenesis (21,22). In contrast, the Hippo pathway, by inactivating YAP, inhibits angiogenesis and tissue repair (42). Here we show that dysregulation of Hippo-YAP signaling is also responsible for PA-induced inhibition of angiogenesis. PA treatment activated MST1 and subsequently inhibited YAP, leading to the inhibition of endothelial proliferation and tube formation. This finding implies that dysregulation of Hippo-YAP may represent an important mechanism underlying impaired angiogenesis and wound healing in diabetes.
Several triggers and molecules such as reactive oxygen species (43,44), thioredoxin-interacting protein (13), and protein-tyrosine phosphatase 1B (45) have been implicated in the inhibition of angiogenesis in diabetes. Mitochondrial dysfunction and damage are significant features in diabetes (46,47). Mitochondrial damage induced by metabolic stress (48) triggers endothelial dysfunction and injury, contributing to the development of cardiovascular diseases (48 -50).
Here we show that mitochondrial damage is an important mechanism responsible for PA-induced angiogenesis inhibition. We show that PA-induced mtDNA release to cytosol, which may activate cytosolic DNA sensor cGAS-STING-IRF3 signaling, leading to up-regulation of MST1 and inhibition of YAP and angiogenesis. Thus, mitochondrial damage, in addition to inducing endothelial dysfunction and inflammation, can also inhibit endothelial angiogenesis. Protecting mitochondria from damage and/or promoting the removal of damaged mitochondria may be critical in preserving endothelial angiogenesis capacity.
The Hippo-YAP pathway can be regulated by multiple mechanisms such as cell-cell interaction and mechanical signals, and by various signaling pathways (25). Although pathways such as PI3-kinase signaling activate YAP (51), tumor suppressors activate the Hippo pathway and inactivate YAP (52,53). Here, we identified a new signaling pathway, the proinflammatory DNA sensor cGAS-STING-IRF3 pathway as a trigger showed that PA triggered dsDNA release to cytosol (white arrows, dsDNA that did not co-localize with either mitochondria or the nucleus) (n ϭ 6 biological repeats). C, PCR analysis of mtDNA in cytosolic fractions showed that PA treatment increased cytosolic mtDNA (n ϭ 4 biological repeats). D, Western blot analysis showed that PA activated cGAS, STING, IRF3, and MST1 (n ϭ 3 biological repeats). E and F, HAECs were treated with CCCP for 24 h. Western blot analysis showed up-regulation of cGAS, STING, and IRF3 by CCCP treatment (n ϭ 6 biological repeats) (E). Representative images of immunostaining showed that CCCP treatment induced STING perinuclear translocation and IRF3 nuclear translocation (n ϭ 4 biological repeats) (F).

Cross-talk between DNA sensor signaling and Hippo-Yap pathway
for Hippo pathway activation and YAP inhibition. We found that the cGAS-STING-IRF3 pathway was involved in dysregulation of the Hippo-YAP pathway in endothelial cells. IRF3 directly bound to the MST1 promoter and induced MST1 expression, leading to YAP phosphorylation and inactivation, and angiogenesis inhibition. Interestingly, a recent study showed that MST1 directly phosphorylated and inactivated IRF3, reduced IRF3 dimerization, and DNA-binding and transcription activity (54). Thus, the cross-talk between the Hippo-YAP and the cGAS-STING-IRF3 pathways can be highly specific to factors such as cell types and stress conditions. Whether the cGAS-STING-IRF3 pathway can also activate Hippo-YAP signaling under other stimulators (e.g. hyperglycemia) or in other cells (e.g. inflammatory cells) remains to be determined.
The cGAS-STING-IRF3 pathway plays a critical role in the innate immune response by promoting the expression of genes that suppress pathogen replication or facilitate adaptive immunity (55,56). Recent studies suggest that STING is also involved in inflammation (8,57). Gain-of-function mutations in STING have been identified in an autoinflammatory disease characterized by early-onset systemic inflammation and vasculopathy (8) and in familial inflammatory syndrome (58). Here our in vitro study shows that activation of the STING pathway is also involved in metabolic stress-induced angiogenesis inhibition. However, further in vivo studies are needed to determine whether this pathway plays a role in angiogenesis defects in diabetes, or whether wound healing in the diabetic condition can be improved by genetic deletion or pharmacological inhibition of STING.

Conclusions
Our study has demonstrated that PA dysregulates the Hippo-YAP pathway and inhibits endothelial angiogenesis. PA induces mtDNA cytosolic release and activates the cytosolic DNA sensor cGAS-STING-IRF3 pathway, which promotes MST1 expression, leading to inhibition of YAP and endothelial angiogenesis. This mechanism may have implications in impaired wound healing in diabetes.

Cell culture
Cells were cultured as described previously (27,28). Primary HAECs was purchased from ScienCell Research Laboratories (CA) and cultured in endothelial cell medium (ScienCell Research Laboratories) supplemented with 5% fetal bovine serum, endothelial cell growth factors, and penicillin/streptomycin solution.    China). The best siRNA for each gene was selected and used in our study. pcDNA4/HisMaxB-YAP1-S127A (number 18988, Addgene) and pcDNA4/HisMaxB-YAP1 (number 18978, Addgene) were used in this study. HAECs were transfected with 0.5 g of plasmids and then treated with PA for 24 h. Cell transfection was performed with Lipofectamine 2000 (12566014, Thermo Fisher Scientific Inc.), and for siRNA and Lipofectamine 3000 transfection reagent (L3000015, Thermo Fisher Scientific Inc.) for overexpression according to the manufacturer's instructions.

Palmitic acid preparation and treatment
Saturated PA was used in this study. PA preparation and treatment were performed as described previously (27,28,59). Briefly, PA was dissolved in ethanol into a 200 mM solution, and combined with 20% free fatty acid-free BSA to produce stock solutions with different concentrations from 1 to 5 mM. These stock solutions were filter-sterilized and stored at Ϫ20°C. A control solution containing ethanol and BSA was similarly prepared. For the experiments, fresh working solutions were prepared by diluting each stock solution (1:10) in the endothelial cell medium. The final BSA concentration was constant in all PA working solutions, whereas the PA to BSA ratio varied with the PA concentrations.

BrdU proliferation assay
5-Bromo-2-deoxyuridine (BrdU) was used to detect the rate of cell proliferation. HAECs with a confluence of 50 -70% on coverslips in 24-well cell culture plates were treated with PA for 24 h and 10 g/ml of BrdU during the last 6 h. The treated cells were washed with PBS, fixed in 4% polyformaldehyde at room temperature for 30 min, and permeabilized with 0.5% Triton X-100 for 10 min. The DNA was denatured with 2 mol/liter of HCl for 1 h and the solution was neutralized with 0.1 mol/liter of sodium borate (pH 8.3) for 20 min. The cells on the coverslips were blocked with 1% BSA at room temperature for 1 h, incubated with anti-BrdU antibody at 4°C overnight, Alexa Fluor 488-conjugated secondary antibodies (1:500, Invitrogen) at room temperature for 1 h, and DAPI nuclear staining for 10 min. The cells were observed under a Nikon eclipse Ti and UltraVIEW VOX confocal microscope. BrdUϩ cells and total cells in 5 randomly selected fields per sample were counted. The ratio of BrdUϩ cells/total cells (%) was compared between the groups.

Flow cytometry of BrdU proliferation assay
Flow cytometry was used to quantify the BrdU proliferation assay (60). Briefly, cells were cultured in 6-well plates and 10 g/ml of BrdU was added during the last 6 h. Cells were harvested by a 0.125% trypsin solution, centrifuged, and resuspended in PBS and fixed by shaking gently on a shaking table in 4% polyformaldehyde for 30 min at room temperature, then centrifuged at 1000 rpm for 10 min, and washed by PBS, permeabilized with 0.5% Triton X-100 for 10 min, after being washed. The DNA was denatured with 2 mol/liter of HCl for 1 h and the solution was neutralized with 0.1 mol/liter of sodium borate (pH 8.3) for 20 min. 1% BSA was added for 1 h at room temperature after PBS and cells were kept on a gently shaking table, then stained with anti-BrdU antibody (BU1/75 (ICR1)) (FITC) (ab74545, Abcam, ShangHai, China) cells at 4°C overnight under shaking. Data were analyzed and shown by kaluza 1.5a and Flowjo 10.0.

Migration assay
Scratch assay was performed to evaluate cell migration. Briefly, HAECS with 100% confluence in 6-well plates were scratched with 200-l pipette tips. At 4, 8, 12, and 24 h after scratch, the areas of the gap were imaged and measured using ImageJ software. The migrated area was calculated as the initial gap area subtracted by the current gap area. The migration was presented as the ratio of the migrated area/the initial gap area. The area of gap at each time point was compared between the groups.

Matrigel tube formation assay
Matrigel (354248, BD Biosciences, Corning, NY) was added to the wells of 96-well culture plates, and concentrated at 37°C for 0.5-1 h. Treated HAECs were harvested and seeded into the Matrigel containing wells. The total tube length were recorded at 4 and 12 h and calculated by ImageJ.

Western blot analysis
Western blot analysis was performed as described before (27,28,59). Protein lysates were extracted from the treated cells, separated by SDS-polyacrylamide gels, and then transferred to the polyvinylidine fluoride membranes. The membranes blocked with antibodies were incubated at 4°C overnight, the secondary horseradish peroxidase-labeled antibody was incubated for 1 h in room temperature, bands were photographed by Alpha FluorChem E system and analyzed by ImageJ. Primary antibodies used were anti-phospho-YAP (Ser-127) (rabbit mAb, 13008, CST Shanghai, China), anti-YAP (12395, CST Shanghai, China), anti-phospho-MST1/MST2 (T180/T183) antibody (ab76323, Abcam, Shanghai, China), anti-MST1 antibody (ab51134, Abcam), anti-STING antibody (ab131604, Figure 7. cGAS-STING-IRF3 signaling is involved in PA-induced inhibition of endothelial angiogenesis. HAECs were transfected with scramble siRNA, cGAS siRNA, STING siRNA, or IRF3 siRNA, and then treated with PA for 24 h. A and B, representative images (n ϭ 5 biological repeats) (A) and flow cytometry analysis (n ϭ 4 biological repeats) (B) of the BrdU proliferation assay showed that silencing cGAS, STING, or IRF3 prevented PA-induced inhibition of endothelial proliferation. C, tube formation assay showed that knocking down cGAS, STING, or IRF3 reversed PA-induced inhibition of endothelial angiogenesis (n ϭ 5 biological repeats). D, proposed mechanism of PA-induced inhibition of angiogenesis. PA causes mitochondrial damage and cytosolic release of mtDNA, which is converted to cGAMP by cGAS. cGAMP activates STING, which facilitates TBK-1-mediated IRF3 phosphorylation/activation. Activated IRF3 enters the nucleus, binds to the MST1 promoter, and induces MST1 expression. MST1 promotes YAP phosphorylation and cytosolic retention, leading to inhibition of endothelial angiogenesis.

Real-time quantitative RT-PCR
We use TRIzol and chloroform to extract total RNA from the treated cells, PrimeScript TM RT reagent Kit (RR037A, Takara) helps to reverse the RNA transcribed into cDNAs. Real-time PCR were tested and quantified using a CFX Connect TM Fluorescent quantitative PCR detection system. Sequences of primers are shown as supplemental Table S1.

Mitochondrial transmembrane potential determination
JC-1 (C2006, Beyotime, China) was used to measure mitochondrial transmembrane potential, the experiment was carried as described (37) following the manufacturer's instructions.

Measurement of mtDNA in the cytosol
The experiment was carried out as described previously (28,36). In brief, cells were treated with PA, lysed in cell lysis buffer (Thermo Fisher, Foster City, CA), and centrifuged at 700 ϫ g for 10 min at 4°C to remove the nuclei and intact cells. The volume of the supernatant was normalized according to the protein concentration. The cell lysate was further centrifuged at 10,000 ϫ g for 30 min at 4°C to isolate the cytosolic fraction, and then the DNA in the cytosolic fraction was isolated. The mtDNA was detected by quantitative PCR by using sequences in the gene coding for mitochondrial cytochrome c oxidase 1 (mtCOI) as primers. The nuclear DNA was measured by PCR by using sequences in the 18S rDNA (coding 18S ribosomal RNA) as primers. The copy numbers of mtDNA were normalized against the copy numbers of nuclear DNA. The primers for 18S rDNA were 5Ј-TAGAGGGACAAGTGGCGTTC-3Ј (forward) and 5Ј-CGCTGAGCCAGTCAGTGT-3Ј (reverse). The primers for human mtCOI were 5Ј-GCCCCCGATATG-GCGTTT-3Ј (forward) and 5Ј-GTTCAACCTGTTCCTGC-TCC-3Ј (reverse). The fluorescent quantitative PCR detection system CFX Connect TM helped to achieve the test.

Chromatin immunoprecipitation assay
We use the EZ-ChIP TM Kit (Merck Millipore) to complete this assay, the process was carried as described before (28) and following the manufacturer's protocol. In brief, PA-treated cells were first incubated with 1% formaldehyde at room temperature for 10 min, then ϫ10 glycine was added to quench the unreacted formaldehyde. The cells were then washed, harvested, and lysed. Cell lysates were sonicated and centrifuged to produce chromatin fragments 200 -1000 base pairs in length. Then, the immunoprecipitation procedure was performed with an anti-IRF3 antibody (number 4302, CST) and protein A-agarose slurry (IgG served as the negative control). The immunocomplex beads were then washed sequentially with low-salt wash buffer, high-salt wash buffer, LiCl wash buffer, and Tris-EDTA buffer. The immunocomplex was eluted with elution buffer (100 mmol/liter of NaHCO 3 , 1% SDS). The eluted immunocomplex and the input were incubated with 200 mM NaCl at 65°C overnight and then incubated with proteinase K to digest the remaining proteins. The DNA was recovered by phenol/ chloroform/isoamyl alcohol extraction and used as a template for PCR. Real-time quantitative PCR was performed to quantify the DNA, and the results were analyzed by using the comparative ⌬C t method. The size and purity of the PCR products were checked by analyzing the products with gel electrophoresis in 2% agarose gel. The sequences of primers that IRF3 binds to MST1 was shown in Fig. 6B.

Immunofluorescence and confocal imaging
The PA-treated cells were washed with PBS and fixed by 4% polyformaldehyde for 30 min at room temperature, and then permeabilized with 0.5% Triton X-100 for 10 min. 1% BSA was added to block the cells for 1 h at room temperature, and different antibodies were stained with cells at 4°C for overnight. The cells was incubated with fluorescent-labeled secondary antibodies on the second day for 1 h and DAPI nuclear staining for 10 min at room temperature. For mitochondrial and cytolic DNA staining, before fixing cells, MitoTracker (M22426, Invitrogen) was added and incubated with cells for 30 min and anti-dsDNA antibody was used as the primary antibody. The cells were observed under Nikon eclipse Ti and UltraVIEW VOX confocal microscope. Primary antibodies used for immunostaining were: YAP antibody (1:200, number 12395, CST), STING antibody (1:100, number 13647, CST), IRF3 antibody (1:100, number 4302,CST), and dsDNA antibody (1:300, number ab27156, Abcam). Secondary antibodies used for immunostaining were: Alexa Fluor 488-conjugated secondary antibodies (1:500, A32723, Invitrogen) and Alexa Fluor 647-conjugated secondary antibodies (1:500, A32733 Thermo Fisher).

Statistical analysis
All quantitative variables are presented as the mean Ϯ S.D. Two-group comparisons were performed by using the two sample t test. Multigroup comparisons were performed by using one-way analysis of variance. For all statistical analyses, two-tailed probability values were reported. p Ͻ 0.05 was considered statistically significant.